pharma news

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Joy as NICE changes tack on first NHS vitiligo treatment

NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA maps new regulatory route for ultra-rare diseases

The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

After CagriSema blow, Novo reveals data for obesity 'triple'

Joy as NICE changes tack on first NHS vitiligo treatment

MSD splits pharma business, hiving off oncology

FDA maps new regulatory route for ultra-rare diseases

FDA clears first all-oral combo for first-line CLL treatment

Gilead buys cell therapy partner Arcellx for up to $7.8bn

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks